(XENE) Xenon Pharmaceuticals - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 5.232m USD | Total Return: 77.7% in 12m
Avg Turnover: 46.3M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Xenon Pharmaceuticals Inc. (XENE) is a clinical-stage biopharmaceutical company focused on developing therapeutics for neurological and psychiatric disorders. Its lead candidate, Azetukalner, is a Kv7 potassium channel opener currently in Phase 3 trials for epilepsy and major depressive disorder. The company also maintains a pipeline of early-stage sodium channel inhibitors and holds a strategic collaboration with Neurocrine Biosciences.
The biotechnology sector often relies on high-capital R&D and strategic licensing agreements to advance drug candidates through the multi-stage FDA approval process. Unlike commercial-stage firms, clinical-stage companies like Xenon generate value primarily through clinical trial milestones and intellectual property development. For a deeper look into the companys valuation metrics, consider reviewing the data on ValueRay.
Headquartered in Burnaby, Canada, Xenon has operated since 1996, diversifying its portfolio to include treatments for both focal onset seizures and chronic pain management. Its technical approach targets specific ion channels, such as Nav1.2/1.6 and Kv7, to modulate neuronal activity.
- Azetukalner Phase 3 clinical trial results drive primary valuation and market sentiment
- FDA approval timeline for focal onset seizures dictates near-term commercial viability
- Expansion of Azetukalner into major depressive disorder increases total addressable market
- Collaboration milestones and royalty payments from Neurocrine Biosciences impact cash runway
- Competition from established anti-seizure medications affects long-term peak sales projections
| Net Income: -383.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 4.93 > 1.0 |
| NWC/Revenue: 14.2k% < 20% (prev 5.33k%; Δ 8.90k% < -1%) |
| CFO/TA -0.22 > 3% & CFO -306.4m > Net Income -383.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 27.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (87.3m) vs 12m ago 11.00% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.70% > 50% (prev 1.35%; Δ -0.64% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.77 (Total Current Assets 1.11b - Total Current Liabilities 39.8m) / Total Assets 1.39b |
| B: -0.97 (Retained Earnings -1.35b / Total Assets 1.39b) |
| C: -0.38 (EBIT TTM -401.5m / Avg Total Assets 1.07b) |
| D: 21.90 (Book Value of Equity 1.07b / Total Liabilities 49.0m) |
| Altman-Z'' = 22.34 = AAA |
| DSRI: 0.18 (Receivables 1.17m/8.65m, Revenue 7.50m/10.0m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.89 (AQ_t 0.19 / AQ_t-1 0.22) |
| SGI: 0.75 (Revenue 7.50m / 10.0m) |
| TATA: -0.06 (NI -383.2m - CFO -306.4m) / TA 1.39b) |
| Beneish M = -4.00 (Cap -4..+1) = AAA |
As of May 24, 2026, the stock is trading at USD 54.12 with a total of 1,133,690 shares traded.
Over the past week, the price has changed by -0.40%,
over one month by -4.38%,
over three months by +26.80% and
over the past year by +77.66%.
Xenon Pharmaceuticals has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy XENE.
- StrongBuy: 14
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 79.2 | 46.3% |
P/B = 3.9105
P/EG = -0.06
Revenue TTM = 7.50m USD
EBIT TTM = -401.5m USD
EBITDA TTM = -399.0m USD
Long Term Debt = 5.93m USD (estimated: total debt 7.49m - short term 1.56m)
Short Term Debt = 1.56m USD (from shortTermDebt, last quarter)
Debt = 7.49m USD (from shortLongTermDebtTotal, last quarter) (leases 7.49m already included)
Net Debt = -1.09b USD (calculated: Debt 7.49m - CCE 1.09b)
Enterprise Value = 4.14b USD (5.23b + Debt 7.49m - CCE 1.09b)
Interest Coverage Ratio = unknown (Ebit TTM -401.5m / Interest Expense TTM 0.0)
EV/FCF = -13.49x (Enterprise Value 4.14b / FCF TTM -307.3m)
FCF Yield = -7.41% (FCF TTM -307.3m / Enterprise Value 4.14b)
FCF Margin = -4.10k% (FCF TTM -307.3m / Revenue TTM 7.50m)
Net Margin = -5.11k% (Net Income TTM -383.2m / Revenue TTM 7.50m)
Gross Margin = unknown ((Revenue TTM 7.50m - Cost of Revenue TTM 78.9m) / Revenue TTM)
Tobins Q-Ratio = 2.99 (Enterprise Value 4.14b / Total Assets 1.39b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 7.49m)
Taxrate = 21.0% (US default 21%)
NOPAT = -317.2m (EBIT -401.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 27.79 (Total Current Assets 1.11b / Total Current Liabilities 39.8m)
Debt / Equity = 0.01 (Debt 7.49m / totalStockholderEquity, last quarter 1.34b)
Debt / EBITDA = 2.72 (negative EBITDA) (Net Debt -1.09b / EBITDA -399.0m)
Debt / FCF = 3.54 (negative FCF - burning cash) (Net Debt -1.09b / FCF TTM -307.3m)
Total Stockholder Equity = 778.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.98% (Net Income -383.2m / Total Assets 1.39b)
RoE = -18.02% (Net Income TTM -383.2m / Total Stockholder Equity 2.13b)
RoCE = -18.83% (EBIT -401.5m / Capital Employed (Equity 2.13b + L.T.Debt 5.93m))
RoIC = -52.05% (negative operating profit) (NOPAT -317.2m / Invested Capital 609.4m)
WACC = 6.27% (E(5.23b)/V(5.24b) * Re(6.28%) + D(7.49m)/V(5.24b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 6.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 10.36%
[DCF] Fair Price = unknown (Cash Flow -307.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.65 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.50 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.16 | Chg30d=+1.34% | Revisions=+20% | Analysts=14
EPS next Quarter (2026-09-30): EPS=-1.19 | Chg30d=+0.86% | Revisions=+33% | Analysts=14
EPS current Year (2026-12-31): EPS=-4.81 | Chg30d=+0.34% | Revisions=-6% | GrowthEPS=-10.3% | GrowthRev=-66.6%
EPS next Year (2027-12-31): EPS=-5.01 | Chg30d=-5.88% | Revisions=-29% | GrowthEPS=-4.1% | GrowthRev=+1502.5%
[Analyst] Revisions Ratio: +33%